Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML

Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial

(2022) Huafeng Wang et al.   Lancet Haematology

Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia

(2022) Sangeetha Venugopal et al.   AMERICAN JOURNAL OF HEMATOLOGY

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

(2021) Courtney D. DiNardo et al.   JOURNAL OF CLINICAL ONCOLOGY

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

(2021) Tapan M Kadia et al.   Lancet Haematology

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia

(2021) Evan M. Cherry et al.   Blood Advances

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients

(2020) Shanshan Pei et al.   Cancer Discovery

Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial

(2020) Andrew Henry Wei et al.   BLOOD

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia

(2020) Tobias Herold et al.   LEUKEMIA

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

(2020) Christoph Röllig et al.   BLOOD

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial

(2020) Amy Burd et al.   NATURE MEDICINE

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

(2019) Andrew H. Wei et al.   JOURNAL OF CLINICAL ONCOLOGY

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

(2018) Courtney D. DiNardo et al.   BLOOD

Functional genomic landscape of acute myeloid leukaemia

(2018) Jeffrey W. Tyner et al.   NATURE

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study

(2010) S. Ohtake et al.   BLOOD

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE